Clinical Trial Update: Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of Vandetanib in combination with Etoposide for malignant gliomas (glioblastoma and gliosarcoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Etoposide (Etoposide)
• Vandetanib (vandetanib)

Snippet

Sponsor: Annick Desjardins | Conditions: Gliosarcoma, Glioblastoma | Phase 1 | Status: COMPLETED